Is this the end of glaucoma-related vision loss? by Dr David Sinclair #eyehealth #future

Could we one day restore damaged vision by reprogramming cells? Dr. David Sinclair is discussing new interim results from Life Biosciences’ Phase 1 trial of ER-100, an experimental therapy based on research into epigenetic restoration. The approach aims to restore aspects of cellular function by targeting epigenetic changes associated with aging. According to the company’s announcement, three participants with open-angle glaucoma received a single injection into the eye alongside daily doxycycline. The treatment was reported to be well tolerated through day 56, with preliminary signals of improvement in visual field testing in two participants. These findings are an early step, not proof that the treatment restores vision or reverses aging in humans. Phase 1 trials primarily evaluate safety and tolerability, and larger studies will be needed to determine whether the treatment is effective. The bigger takeaway: Epigenetic reprogramming is moving from laboratory research toward human trials. The science is exciting, but the key question now is whether these early signals translate into meaningful, lasting benefits for patients. Fair Use Disclaimer: This content is shared for educational and commentary purposes under fair use. Medical Disclaimer: This content is for educational purposes only and is not medical advice. #DavidSinclair #Epigenetics #Glaucoma #Biotechnology #Longevity Disclaimer: The content contained in this video, and its accompanying description, is not intended to replace viewers’ relationships with their own medical practitioner. Always speak with your doctor regarding the content of this channel, and especially before using any products, services, or devices discussed on this channel. All materials in these videos are used for educational purposes and fall within the guidelines of fair use. No copyright infringement intended. If you are or represent the copyright owner of materials used in this video and have a problem with the use of said material, please send us an email, [email protected], and we can sort it out.